Celltrion's COVID-19 antibody therapy Regkirona is pushing for an expansion of indications based on global phase 3. Regkirona was conditionally approved to submit a clinical trial result report for therapeutic confirmation in February and was used only in patients with mild to secondary COVID groups. Celltrion submitted a report on the results of the clinical trial and applied for a change in efficacy from all mild cases over the age of 12 to secondary patients.

The MFDS announced on the 10th that Celltrion has applied for a change in permission of the COVID-19 antibody treatment drug Regkirona (Regdanvimab) based on a global phase 3. Changes include ▲ deletion of permission conditions ▲ expansion of